{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-005069","form_type":"8-K","ticker":"KLRS","cik":"0001754068","company_name":"Kalaris Therapeutics, Inc.","filed_at":"2022-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:08.080850+00:00","generated_at":"2026-06-27T19:32:19.339328+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"AlloVir reports $248.1M cash at year-end 2021; JPM presentation ongoing","bullets":["Unaudited cash, equivalents and marketable securities total $248.1M as of Dec 31, 2021.","Corporate presentation furnished for J.P. Morgan Healthcare Conference on Jan 10, 2022.","AlloVir is a leader in allogeneic, off-the-shelf virus-specific T cell therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-005069","json":"https://secwatch.observer/filing/0001193125-22-005069.json","markdown":"https://secwatch.observer/filing/0001193125-22-005069.md","text":"https://secwatch.observer/filing/0001193125-22-005069.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/0001193125-22-005069-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1754068/000119312522005069/d279555d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T19:32:19.339328+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}